Checklist for standardized reporting of drug-drug interaction management guidelines

Checklist for standardized reporting of drug-drug interaction management guidelines

他のバージョン（1件）を表示する

Purpose: Inconsistencies and omissions in drug-drug interaction (DDI) management guidelines may lead to harm and suboptimal therapy. The purpose of this study was to define a checklist for DDI management guidelines to help developers produce high-quality guidelines that will support healthcare provi...

書誌詳細
主要な著者:	Floor-Schreudering, A, Geerts, A, Aronson, J, Bouvy, M, Ferner, R, De Smet, P
フォーマット:	Journal article
言語:	English
出版事項:	2014

類似資料

Checklist for standardized reporting of drug-drug interaction management guidelines.
著者:: Floor-Schreudering, A, 等
出版事項: (2014)

Towards improved drug-drug interaction management guidelines
著者:: Floor-Schreudering, A, 等
出版事項: (2013)

Pharmacogenetics and adverse drug reactions
著者:: Ferner, R, 等
出版事項: (2010)

Clarification of terminology in drug safety.
著者:: Aronson, J, 等
出版事項: (2005)

Communicating information about drug safety.
著者:: Ferner, R, 等
出版事項: (2006)

Preventability of drug-related harms - part II: proposed criteria, based on frameworks that classify adverse drug reactions.
著者:: Aronson, J, 等
出版事項: (2010)

National differences in publishing papers on adverse drug reactions.
著者:: Ferner, R, 等
出版事項: (2005)

EIDOS: a mechanistic classification of adverse drug effects.
著者:: Ferner, R, 等
出版事項: (2010)

The toxicological significance of post-mortem drug concentrations in bile
著者:: Ferner, RE, 等
出版事項: (2017)

Monitoring for the Adverse Effects of Drugs
著者:: Coleman, J, 等
出版事項: (2008)

Joining the DoTS: new approach to classifying adverse drug reactions.
著者:: Aronson, J, 等
出版事項: (2003)

Preventability of drug-related harms - part I: a systematic review.
著者:: Ferner, R, 等
出版事項: (2010)

Defining rewardable innovation in drug therapy.
著者:: Aronson, J, 等
出版事項: (2012)

A practical guide to monitoring for adverse drug reactions during antihypertensive drug therapy.
著者:: McDowell, SE, 等
出版事項: (2013)

Nominal ISOMERs (Incorrect spellings of medicines eluding researchers)-variants in the spellings of drug names in PubMed: a database review
著者:: Ferner, R, 等
出版事項: (2016)

Spontaneous reporting to regulatory authorities of suspected adverse drug reactions to COVID-19 vaccines over time: the effect of publicity
著者:: Ferner, RE, 等
出版事項: (2022)

Serious drug interactions.
著者:: Aronson, J
出版事項: (1993)

Classifying drug interactions.
著者:: Aronson, J
出版事項: (2004)

Beneficial drug interactions.
著者:: Aronson, J
出版事項: (1994)

Publishing histories of adverse reactions to medicaments anecdotally: the PHARMA guidelines for reporting suspected adverse drug reactions.
著者:: Aronson, J
出版事項: (2008)

Designing and Psychometry of the Evaluation Checklist for the Registration and Labeling Guidelines of Anesthetic Drugs in the Operating Room
著者:: Parisa Moradimajd, 等
出版事項: (2023-01-01)

Reporting guidelines for human microbiome research: the STORMS checklist
著者:: Mirzayi, C, 等
出版事項: (2021)

Communicating information about drug interactions
著者:: Aronson, J
出版事項: (2007)

Interactions that matter: 10 Antiarrhythmic drugs
著者:: Aronson, J
出版事項: (1987)

Reporting guideline checklists are not quality evaluation forms: they are guidance for writing
著者:: Logullo, P, 等
出版事項: (2020)

Meyler's side effects of drugs : the international encyclopedia of adverse drug reactions and interactions /
著者:: Aronson, Jeffrey K.
出版事項: (2006)

Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.
著者:: Aronson, J
出版事項: (2005)

The reporting checklist for public versions of guidelines: RIGHT-PVG
著者:: Xiaoqin Wang, 等
出版事項: (2021-01-01)

RMJ research series – Using a Reporting Guideline (Checklist)
著者:: D. Hopkinson, 等
出版事項: (2020-03-01)

Checking and correction of drug information in the standards of care and clinical guidelines
著者:: B. K. Romanov
出版事項: (2018-02-01)

Clinical pharmacology. Adverse drug interactions.
著者:: Aronson, J, 等
出版事項: (1981)

Reporting Guidelines for Healthcare Guideline Adaptations: An Interpretation of the RIGHT-Ad@pt Checklist
著者:: GONG Liyun, 等
出版事項: (2024-11-01)

Drug interactions-information, education, and the British National Formulary.
著者:: Aronson, J
出版事項: (2004)

Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.
著者:: Hauben, M, 等
出版事項: (2007)

STAGER checklist: Standardized testing and assessment guidelines for evaluating generative artificial intelligence reliability
著者:: Jinghong Chen, 等
出版事項: (2024-09-01)

The reporting checklist for Chinese patent medicine guidelines: RIGHT for CPM
著者:: Xuanlin Li, 等
出版事項: (2024-01-01)

iCHECK-DH: Guidelines and Checklist for the Reporting on Digital Health Implementations
著者:: Caroline Perrin Franck, 等
出版事項: (2023-05-01)

Guidelines of research biosimilar drugs
著者:: R. . Ivanov, 等
出版事項: (2014-04-01)

Pharmacokinetic drug-drug interaction and their implication in clinical management
著者:: Palleria Caterina, 等
出版事項: (2013-01-01)

Adverse drug reactions: definitions, diagnosis, and management.
著者:: Edwards, I, 等
出版事項: (2000)